Hidehiko Okazawa, Tomoya Uehara, Ichiei Kuji, Tatsuya Higashi, Mana Yoshimura
{"title":"[第 45 次放射性药物不良反应调查报告（2022 年第 48 次调查）]。","authors":"Hidehiko Okazawa, Tomoya Uehara, Ichiei Kuji, Tatsuya Higashi, Mana Yoshimura","doi":"10.18893/kakuigaku.rp.2431","DOIUrl":null,"url":null,"abstract":"<p><p>This survey was performed in order to investigate the incidence of adverse reactions to radiopharmaceuticals in FY2022 in Japan. It was based on responses to questionnaires sent to nuclear medicine institutions. Replies were obtained from 1,004 institutions out of 1,181 to which the questionnaire had been sent. A total of 911,977 radiopharmaceutical administrations were reported. Seventeen cases of adverse reactions were reported. The incidence of adverse reactions per 100,000 cases was 1.9 . No case of defective products was reported.</p>","PeriodicalId":94120,"journal":{"name":"Kaku igaku. The Japanese journal of nuclear medicine","volume":"61 1","pages":"1-12"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[The 45th Report on Survey of the Adverse Reaction to Radiopharmaceuticals (The 48th Survey in 2022)].\",\"authors\":\"Hidehiko Okazawa, Tomoya Uehara, Ichiei Kuji, Tatsuya Higashi, Mana Yoshimura\",\"doi\":\"10.18893/kakuigaku.rp.2431\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This survey was performed in order to investigate the incidence of adverse reactions to radiopharmaceuticals in FY2022 in Japan. It was based on responses to questionnaires sent to nuclear medicine institutions. Replies were obtained from 1,004 institutions out of 1,181 to which the questionnaire had been sent. A total of 911,977 radiopharmaceutical administrations were reported. Seventeen cases of adverse reactions were reported. The incidence of adverse reactions per 100,000 cases was 1.9 . No case of defective products was reported.</p>\",\"PeriodicalId\":94120,\"journal\":{\"name\":\"Kaku igaku. The Japanese journal of nuclear medicine\",\"volume\":\"61 1\",\"pages\":\"1-12\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Kaku igaku. The Japanese journal of nuclear medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18893/kakuigaku.rp.2431\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kaku igaku. The Japanese journal of nuclear medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18893/kakuigaku.rp.2431","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
[The 45th Report on Survey of the Adverse Reaction to Radiopharmaceuticals (The 48th Survey in 2022)].
This survey was performed in order to investigate the incidence of adverse reactions to radiopharmaceuticals in FY2022 in Japan. It was based on responses to questionnaires sent to nuclear medicine institutions. Replies were obtained from 1,004 institutions out of 1,181 to which the questionnaire had been sent. A total of 911,977 radiopharmaceutical administrations were reported. Seventeen cases of adverse reactions were reported. The incidence of adverse reactions per 100,000 cases was 1.9 . No case of defective products was reported.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
